Article

Novel human erythrovirus associated with transient aplastic anemia.

Laboratoire de Virologie, Hôpital Armand Trousseau (EA 2391 UFR Saint-Antoine), 75 571 Paris Cedex 12, France.
Journal of Clinical Microbiology (Impact Factor: 4.23). 08/1999; 37(8):2483-7.
Source: PubMed

ABSTRACT Erythrovirus (formerly parvovirus) B19 causes a wide range of diseases in humans, including anemia due to aplastic crisis. Diagnosis of B19 infection relies on serology and the detection of viral DNA by PCR. These techniques are usually thought to detect all erythrovirus field isolates, since the B19 genome is known to undergo few genetic variations. We have detected an erythrovirus (V9) markedly different from B19 in the serum and bone marrow of a child with transient aplastic anemia. The B19 PCR assay yielded a product that hybridized only very weakly to the B19-specific probe and whose sequence diverged more from those of 24 B19 viruses (11 to 14%) than the divergence found within the B19 group (</=6.65%). Restriction enzyme analysis of the V9 genome revealed that this genetic divergence extended beyond the amplified region. Interestingly, serological tests failed to demonstrate a response characteristic of acute B19 infection. V9 could be a new erythrovirus, and new diagnostic tests are needed for its detection.

0 Followers
 · 
110 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunocompromised patients may develop severe chronic anaemia when infected by human parvovirus B19 (B19V). However, this is not the case in human immunodeficiency virus (HIV)-infected patients with good adherence to highly active antiretroviral treatment (HAART). In this study, we investigated the clinical evolution of five HIV-infected patients receiving HAART who had B19V infections confirmed by serum polymerase chain reaction. Four of the patients were infected with genotype 1a strains and the remaining patient was infected with a genotype 3b strain. Anaemia was detected in three of the patients, but all patients recovered without requiring immunoglobulin and/or blood transfusions. In all cases, the attending physicians did not suspect the B19V infections. There was no apparent relationship between the infecting genotype and the clinical course. In the HAART era, B19V infections in HIV-positive patients may be limited, subtle or unapparent.
    Memórias do Instituto Oswaldo Cruz 04/2014; 109(2):168-73. DOI:10.1590/0074-0276140312 · 1.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parvovirus B19 (B19V) is a minute ssDNA virus associated with a wide range of diseases from childhood erythema to fetal death. After primary infection, the viral genomes persist lifelong in solid tissues of most types. Quantification of the viral DNA is important in the timing of primary infection, assessment of tissue persistence and screening of blood donor plasma. In this study, we present a new PCR assay for detection and quantification as well as for differentiation of all three B19V genotypes. A new B19V qPCR was designed to target a 154-bp region of the NS1 area. Serum, plasma and solid tissue samples were suitable for testing in the assay. The WHO International Reference Panel for Parvovirus B19 Genotypes was utilized to validate the assay for detection of different genotypes of B19V in clinical material. Each panel member yielded, by the new qPCR, a quantity similar to the one reported by National Institute for Biological Standards and Control (NIBSC). The qPCR was specific for B19V and amplified and quantified all three genotypes with detection sensitivities of ≤10 copies/reaction. The differentiation of B19V genotypes was performed by Sanger sequencing of the amplified products. Copyright © 2015. Published by Elsevier B.V.
    Journal of virological methods 03/2015; DOI:10.1016/j.jviromet.2015.03.006 · 1.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: El parvovirus B19 fue descubierto de manera fortuita por Yvonne Cossart [28] en 1975, durante una detección selectiva del antígeno HBs en el suero de donantes de sangre. En 7 981, John Pattison [92] y más tarde, en 1983, Mary Anderson [5] le atribuyeron la responsabilidad de la presencia de la eritroblastopenia aguda observada en las hemolisis crónicas y del exantema infeccioso o quinta enfermedad infantil, respectivamente. A lo largo de 25 años, la importancia de este virus en relación con diversos trastornos hematológicos, obstétricos, cardiológicos y reumáticos ha seguido en aumento. Todavía no se ha definido con precisión el papel que podría desempeñar en las vasculitis y en las enfermedades del tejido conjuntivo. La familia Parvoviridae está formada por virus sin envoltura de unos 20 nm de diámetro, con una cápside icosaédrica que contiene una molécula genomica de ácido desoxirribonucleico (ADN) de una sola hebra con alrededor de 5 500 nucleótidos. Se han identificado dos subfamilias, Densovirinae y Parvovirinae. En la primera se agrupan los parvovirus que infectan a insectos y en la segunda, los que infectan a los vertebrados; esta última comprende a su vez dos géneros, dependovirus y eritrovirus, que infectan al hombre. Los parvovirus del género dependovirus necesitan efectuar su ciclo de replicación con ayuda de otros virus, en especial adenovirus; de ahí que se les conozca también con el nombre de virus adenoasociados o AAV. Por el momento no se ha descrito ninguna enfermedad humana asociada a ellos, lo que ha permitido su uso como agentes vectores de genes terapéuticos. Por su parte, en el género eritrovirus existe un solo virus patógeno para el hombre, el parvovirus B19 [29]. Dicho virus muestra un tropismo diferente por los precursores eritroides, BFU-E-CFU-E [84]. El diagnóstico virológico se basa fundamentalmente en la demostración del ácido nucleico viral y en la detección de inmunoglobulinas (Ig) M específicas. El tratamiento es, en la mayor parte de los casos, sintomático, aunque existen tres situaciones que requieren un tratamiento específico: la eritroblastopenia aguda, en la que puede ser necesario efectuar transfusiones de concentrados globulares, la anemia crónica controlable con gammaglobulinas polivalentes, y la exanguino-transfusión intrauterina en caso de anasarca fetoplacentaria.
    01/2006; 38(1):1–6. DOI:10.1016/S1245-1789(03)72045-9

Full-text

Download
69 Downloads
Available from
Jun 3, 2014